Recent advances in Alzheimer's disease (AD) research have revealed a novel fluid‐based biomarker, tau phosphorylated at threonine‐217 (pT217‐tau), in cerebrospinal fluid (CSF) and blood plasma, that reliably discriminates AD from other neurodegenerative diseases.1 Here, MAPT is linked to neurodegenerative disease.